HYALURONAN INDUCED TARGETING

pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable, and intravenous treatment of the following - cancer, increasing activity of macrophages; reduction of swelling in the brain of person suffering brain trauma; herpes, canker sore, shingles; renal failure, cardiac insufficiency, hypertension, edema; infection, acne, monoucleosis; transplants; inflammation, elminiation of tumor breakdown material (toxins and debris), decreasing side effects, relief of pain; detoxification; bronchodilation; vascular ischemia; HIV (AIDS); diabetes; post-menopause; prevention of topical infection; reduction of swelling; hypertension, cardiac insufficiency; prostaglandin synthesis inhibition; enhancement of oxygenation of tissue by perfusion fluid bathing of the tissue (for transplantation purposes); sub-retinal neovascularization and as an adjunct to the treatment of cancer to prevent metastasis; arthitis or pannus; cancer tumours; inhibiting angiogenesis; controlling angiogenesis; regressing angiogenesis; basal cell carcinoma; actinic keratones; liver spots; squamous cell tumours; metastatic cancer of the breast to the skin; primary and metastatic melanoma of the skin; malignancies and/or tumor of the skin; genital warts (condyloma acuminata); cervical cancer; Human Papilloma Virus (HPV); psoriasis, corns on the feet; and hair loss on the heads of pregnant women; topical treatment of pain in the skin and or exposed tissue; clearing of atherosclerosis; prevention of arterial restenosis after balloon angioplasty; macrophage infilitration

acquisition, development and licensing of intellectual property technology regarding pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable and intravenous treatment of medical conditions and disease in humans